Cross-Sector entity

Rhythm Pharmaceuticals

Company RYTM
6

Bardet-Biedl syndrome is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. Rhythm Pharmaceuticals appears in 2 tracked Cross-Sector stories from August 24, 2026.

2 verified stories tracked

Last mentioned: 1d ago

RSS updates
Share

Entity pulse

Recent coverage · Rhythm Pharmaceuticals

2 stories
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Rhythm Pharmaceuticals

Bardet-Biedl syndrome is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. Rhythm Pharmaceuticals appears in 2 tracked Cross-Sector stories from August 24, 2026. The tracked stories average 2 original sources each.

Stories tracked
2
Sources per story
2

Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Rhythm Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Duquesne Family Office initiates RYTM position

    In Q2 2026, Stanley Druckenmiller's investment firm discloses a new stake in Rhythm Pharmaceuticals.

  2. FDA expands Imcivree approval to Bardet-Biedl syndrome

    The indication is expanded to cover obesity associated with Bardet-Biedl syndrome.

  3. FDA approves Imcivree for POMC deficiency

    Imcivree receives U.S. approval for chronic weight management in patients with proopiomelanocortin deficiency.

Stories mentioning Rhythm Pharmaceuticals 2

Healthcare market trends Positive 6

Druckenmiller Bets on 7,500-Patient Rare Obesity Niche RYTM Owns

Rhythm Pharmaceuticals' Imcivree targets rare genetic obesity forms that GLP-1 leaders Eli Lilly and Novo Nordisk don't treat. With a U.S.-Europe market of up to 7,500 patients and a new Druckenmiller-backed position, healthcare stakeholders are watching a distinct orphan drug niche.

2 sources